Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label randomized study of risankizumab versus vedolizumab in target-therapy-naive adults with moderate to severe ulcerative colitis
MOH_2025-03-26_013993Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in autoimmune colitis comparing Risankizumab group with Vedolizumab group (2 arms). Started Mar 2025; status: recruiting.
02
Drugs
risankizumabvedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-03-26_013993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-26_013993.